Dear IPIX Shareholders,
We are pleased to inform you that the site initiation visit for our Phase 1 clinical trial of Brilacidin for Ulcerative Colitis has been completed. Screening of healthy volunteers is in progress, and dosing should commence shortly. The short trial will evaluate the safety, tolerability and pharmacokinetics of oral Brilacidin in healthy volunteers, as well as assess the deliverability of the drug directly to the colon utilizing advanced, delayed-release drug delivery technology.
Shareholder Alert: Site Initiation Visit Completed for Phase 1 Clinical Trial of Brilacidin for Ulcerative Colitis